The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

EHA 2022 | BTK inhibitor-associated adverse events in patients with CLL

Name: BTK inhibitor-associated adverse events in patients with CLL
Uploaded: 2022-06-20T00:00:00Z
Duration: 2 min 18 s
Description: Barbara Eichhorst, MD, University of Cologne, Cologne, Germany, discusses BTK inhibitor-related adverse events in patients with chronic lymphocytic leukemia (CLL), comparing the toxicity profiles of non-specific BTK inhibitors and next-generation BTK inhibitors. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Barbara Eichhorst • 20 Jun 2022

EHA 2022

Chronic Lymphocytic Leukemia Leukemia Acalabrutinib Ibrutinib Pirtobrutinib Zanubrutinib

Barbara Eichhorst, MD, University of Cologne, Cologne, Germany, discusses BTK inhibitor-related adverse events in patients with chronic lymphocytic leukemia (CLL), comparing the toxicity profiles of non-specific BTK inhibitors and next-generation BTK inhibitors. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Dr Eichhorst receives honoraria for presentations and advisory board from several different pharmaceutical companies involved in targeted agents in CLL (Abbvie, BeiGene, BMS, Gilead, Janssen, MSD, Roche).